ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1264

Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study

Kerem Abacar1, Rabia Ergelen2, Fatma Temiz2, Yasin Yildiz2, Tulin Ergun3, Haner Direskeneli4 and Fatma Alibaz-Oner1, 1Marmara University, Rheumatology, Istanbul, Turkey, 2Marmara University, School of Medicine, Departmant of Internal Medicine, Istanbul, Turkey, 3Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, 4Marmara University, Rheumatology, Istanbul, Istanbul, Turkey

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, Imaging, prognostic factors, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: We reported the first controlled ultrasound study showing increased common femoral vein(CFV) thickness in Behçet’s Disease(BD),1 and showed that this is a distinctive feature of BD, rarely present in other inflammatory diseases with a specificity higher than 80% of the cutoff value of ≥0.5 mm.2 This study aimed to assess the prognostic value of CFV thickness during prospective follow-up BD patients.

Methods: We included 195 patients with BD. Bilateral CFV thickness was measured with ultrasonography by an experienced radiologist.Patients were started to follow up prospectively with 3-6 months intervals and in any urgent visit.

Results: At baseline, 98.6% of patients had CFV wall thickness above the cut-off value of ≥0.5 mm(Table 1). 149 patients had prospective follow-up with a mean of 26.03 (16.29) months. New major organ involvement or relapse was seen in 41(27.5%) patients. Among 36 patients with only mucocutaneous disease at baseline, new major organ involvement developed in 9 patients during follow-up. These patients had higher baseline CFV thicknesses compared to patients not developing major organ involvement despite no statistical significance (0.83 mm vs 0.73 mm for right;0.80 mm vs 0.73 mm for left: p >0.05 for both). In 47 patients, the second CFV thickness measurement was done mean 19.8 months later. First and second measurements were found similar (p=0.26, p=0.26 respectively). CFV wall thickness didn’t change with the treatment.

Conclusion: CFV wall thickness measurement which is a new diagnostic tool for BD, does not change over time with treatment modality, new organ involvement or relapses. However, our preliminary results suggest that mucocutaneous BD patients with higher CFV thickness may have a higher risk for the development of major organ involvement during follow-up. The long-term results of our prospective cohort would clarify the prognostic value of CFV thickness in BD.

References 1- Alibaz-Oner F,et al. Clin Rheumatol 2019. 2- Alibaz-Oner F,et al. Rheumatology (Oxford) 2021.

Supporting image 3


Disclosures: K. Abacar, None; R. Ergelen, None; F. Temiz, None; Y. Yildiz, None; T. Ergun, None; H. Direskeneli, None; F. Alibaz-Oner, None.

To cite this abstract in AMA style:

Abacar K, Ergelen R, Temiz F, Yildiz Y, Ergun T, Direskeneli H, Alibaz-Oner F. Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/does-vein-wall-thickness-have-prognostic-value-in-behcets-disease-a-prospective-follow-up-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-vein-wall-thickness-have-prognostic-value-in-behcets-disease-a-prospective-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology